

## Fibrodysplasia ossificans progressiva in a 3-year-old female patient

Cecilia Moreira<sup>1</sup>, Gabriel Dapuerto<sup>2</sup>, Gabriel Peluffo<sup>2</sup>, Alejandra Vomero<sup>2</sup>, Alejandra Tapié<sup>3</sup>, Soledad Rodríguez<sup>3</sup>, Victor Raggio<sup>3</sup>, Rodrigo Suárez<sup>4</sup>, Gustavo Giachetto<sup>5</sup>, and Loreley García<sup>2</sup>

<sup>1</sup>Cuidados Intensivos Pediátricos, Centro Hospitalario Pereira Rossell; <sup>2</sup>Clínica Pediátrica B, Facultad de Medicina, Universidad de la República;

<sup>3</sup>Departamento de Genética, Facultad de Medicina, Universidad de la República; <sup>4</sup>Servicio de Reumatología Infantil, Centro Hospitalario Pereira Rossell; <sup>5</sup>Clínica Pediátrica C, Facultad de Medicina, Universidad de la República. Montevideo, Uruguay

### Abstract

**Background:** Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disease affecting connective tissue, primarily caused by de novo mutations of the ACVR1 gene. FOP is a disease with congenital malformations of the toes and heterotopic ossification in characteristic patterns that progresses with flare-ups and remissions. Cumulative damage results in disability and, eventually, death. This report aimed to describe a case of FOP to highlight the importance of early diagnosis of this rare condition. **Case report:** We describe the case of a 3-year-old female diagnosed with congenital hallux valgus, who initially presented with soft tissue tumors, predominantly in the neck and chest, with partial remission. Multiple diagnostic tests were performed, including biopsies and magnetic resonance imaging, with nonspecific results. We observed ossification of the biceps brachii muscle during evolution. The molecular genetic study found a heterozygous ACVR1 gene mutation that confirmed FOP. **Conclusions:** Knowledge of this rare disease by pediatricians is critical for an early diagnosis and for avoiding unnecessary invasive procedures that may promote disease progression. In case of clinical suspicion, performing an early molecular study is suggested to detect ACVR1 gene mutations. The treatment of FOP is symptomatic and focused on maintaining physical function and family support.

**Keywords:** Myositis ossificans. ACVR1 gene. Hallux valgus.

### Fibrodisplasia osificante progresiva en una paciente de 3 años

### Resumen

**Introducción:** La fibrodisplasia osificante progresiva (FOP) es una enfermedad autosómica dominante rara que afecta el tejido conectivo, cuya causa principal son mutaciones de novo del gen ACVR1. Se trata de una enfermedad con malformaciones congénitas de los primeros orfejos y osificación heterotópica en patrones característicos que progresa en empujes y remisiones. El daño acumulativo provoca discapacidad y, eventualmente, la muerte. El objetivo de este trabajo fue describir un caso de FOP para favorecer el diagnóstico precoz de esta enfermedad infrecuente. **Caso clínico:** Se describe el caso de una paciente de 3 años, portadora de hallux valgus congénito, que inicialmente presentó tumoraciones dolorosas de tejidos blandos, de predominio en cuello y tórax, con remisión parcial de las mismas. Se realizaron múltiples pruebas diagnósticas, incluyendo biopsias e imágenes de resonancia magnética con resultados inespecíficos. En la evolución se

#### \*Correspondence:

Gabriel Dapuerto  
E-mail: gdapuerto@gmail.com

Date of reception: 12-02-2022

Date of acceptance: 19-05-2022

DOI: 10.24875/BMHIM.22000039

Available online: 27-02-2023

Bol Med Hosp Infant Mex. 2023;80(1):69-73

www.bmhim.com

1665-1146/© 2022 Hospital Infantil de México Federico Gómez. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

observó osificación de músculo bíceps braquial. El estudio genético molecular encontró una mutación del gen *ACVR1* en heterocigosis que confirmó el diagnóstico de FOP. **Conclusiones:** El conocimiento de esta enfermedad por los pediatras es clave para realizar un diagnóstico precoz y evitar procedimientos invasivos innecesarios que pueden promover la progresión de la enfermedad. Ante la sospecha clínica, se sugiere realizar tempranamente el estudio molecular para detectar mutaciones del gen *ACVR1*. El tratamiento de la FOP es sintomático, centrado en el mantenimiento de la función física y el apoyo familiar.

**Palabras clave:** Miositis osificante. Gen *ACVR1*. Hallux valgus.

## Introduction

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease, with an estimated incidence of 0.6-1.3 per million individuals<sup>1</sup>, characterized by progressive heterotopic endochondral ossification and congenital malformations of the great toes<sup>2</sup>. It is included in the Online Mendelian Inheritance in Man (OMIM) registry under number 135100<sup>3</sup>.

FOP evolves in flare-ups that produce new areas of ossification, leading to progressive motor disability and death, mainly due to restrictive respiratory complications<sup>4</sup>. It is an autosomal dominant disease caused by heterozygous mutations in the *ACVR1* gene encoding the activin receptor IA (*ACVR1/ALK2*), a protein in the bone morphogenetic signaling pathway<sup>5</sup>.

Although several drugs are used to treat this pathology, there is yet to be a treatment with proven clinical efficacy<sup>1</sup>.

We report the case of a female patient diagnosed with FOP at the age of 3 years. The objective is to inform the case of a rare disease that generated diagnostic difficulties. Knowledge of this entity can avoid unnecessary paraclinical evaluations that can be iatrogenic and favor disease progression.

## Clinical case

We describe the case of a 3-year-old female patient with good growth and development, healthy parents, and two healthy siblings. The patient showed congenital bilateral *hallux valgus* and had a complete immunization scheme. The patient was evaluated for presenting 2-week evolution of multiple painful cervical tumors in both jugular-carotid regions, predominantly on the right side. She showed fever in the first two days of onset of the disease, remaining in apyrexia afterward. No symptoms of intercurrent infection and general compromise were further observed.

Initially, the tumors were of firm-elastic consistency, 3 cm in diameter, and adhered to the muscular planes. They were accompanied by erythema of the overlying

skin, which disappeared during evolution, acquiring a stony consistency. Lymphoganglionic examination revealed multiple mobile adenomegalies in jugular-carotid, submaxillary, axillary, inguinal, and abdominal regions; a painful pole of the spleen was palpated. On admission, the sternocleidomastoid and trapezius muscles had a stony consistency, generating painful torticollis (Figure 1).

During the 2-week hospital stay, tumors with similar characteristics were detected in other regions related to muscular structures: posterior cervical region, trapezius muscles, right subscapular region, and left paravertebral level (Figure 2). The rest of the physical examination showed no alterations.

An anatomopathological study and imaging follow-up of the lesions by ultrasound and magnetic resonance imaging (MRI) were performed. Malignancy and ossification were excluded. The rest of the complementary studies showed no alterations.

During outpatient follow-up after discharge, the patient presented partial regression of the tumors that motivated the initial consultation and similar lesions in the pectoral region, right dorsum, and abdominal wall.


Clinical and functional improvement occurred after initiating treatment with prednisolone at 2 mg/kg. However, the symptomatology returned when this dose was reduced. After five months of evolution, the patient presented pain and limitation of movement. The trapezius and sternocleidomastoid muscles, biceps, and triceps of the right upper limb showed a stony consistency, as well as at the biopsy sample extraction sites. Plain radiography of the right upper limb showed calcification of the right biceps brachii muscle (Figure 3).

The presence of muscular calcifications, in addition to the reevaluation in the diagnostic reasoning of congenital *hallux valgus*—interpreted until now as an isolated morphological alteration—allowed the establishment of the clinical diagnosis of FOP.

The molecular genetic study found *ACVR1*:c.617G>A (p.Arg206His) in heterozygosis, confirming the clinical diagnosis.



**Figure 1.** Hypertrophy of sternocleidomastoid and trapezius muscles.




**Figure 2.** Tumor in the right subscapular region.

## Discussion

This present case is the second case of FOP reported in Uruguay<sup>6</sup>. It is one of the so-called “ultra-rare” diseases, with an estimated incidence of 0.6-1.3 per million individuals. Diagnosis is clinical and confirmed by molecular studies<sup>1,4</sup>. No sex predominance has been established.

This autosomal dominant disease is caused by gain-of-function mutations in the *ACVR1* gene, located on chromosome 2q23-24. More than 95% of patients have the missense mutation c.617G > A (p.Arg206His), as this patient<sup>5</sup>.

The *ACVR1* gene encodes for the activin receptor type IA, a membrane protein member of the family of intercellular signaling protein receptors called bone morphogenetic proteins (BMP) type I<sup>5,7</sup>. The p.Arg206His mutation, which consists of changing the amino acid arginine to histidine at position 206, resides in a domain critical for regulating this protein called the GS (glycine-serine) domain. This change causes a gain of function, leading to constitutive or ligand-independent deregulated activation, which explains its dominant expression. This mutation modifies the folding of the protein at the binding site of another protein (FKBP12) with inhibitory activity on *ACVR1*. The inability to be inactivated by its negative regulator generates



**Figure 3.** Radiographic evidence of ossification of the biceps brachii muscle.

constitutive activity of the receptor encoded by *ACVR1*. The consequent dysregulation of the BMP signaling pathway would lead to aberrant cartilage production from mesenchymal cells<sup>8</sup>.

Morphological alterations of the distal bones of the limbs are one aspect of the disease. Other recurrent mutations in this gene (p.Gly328Arg, p.Gly328Trp, and

p.Gly328Glu) are associated with characteristic limb alterations that may be mistaken for amniotic flange disruptions or type B brachydactyly. The penetrance of gain-of-function mutations in the *ACVR1* gene is estimated to be complete, as no cases with these mutations or their clinical expression have been reported<sup>5</sup>. As in most dominant diseases, wide phenotypic variability can be observed, and other genes and environmental factors likely modulate the presentation of the disease<sup>5</sup>.

As we propose, most cases are sporadic, arising from a *de novo* mutation, since none of the parents have elements suggestive of this condition<sup>1</sup>.

Two clinical elements classically define FOP: malformations of the great toe and progressive heterotopic endochondral ossification in characteristic anatomical patterns. Patients with FOP present as healthy neonates, except for the malformation of the great toe, which is present in all affected individuals, as observed in this case<sup>2,4,9</sup>.

Initially, this patient presented tumors of firm-elastic consistency in the neck, with adherence to muscular planes. This observation led to other diagnoses, including hemato-oncologic causes, usually one of the most frequent initial approaches<sup>10</sup>. Initial imaging studies showed no calcifications, which generated diagnostic confusion. Current evidence demonstrates that the development of heterotopic ossification occurs after soft tissue inflammation<sup>4,11</sup>. Routine biochemical studies are usually normal, as observed in this patient. To date, no specific biomarkers have been identified<sup>1</sup>.

*Hallux valgus* in the pediatric age group is usually acquired during infancy and childhood; it is infrequently congenital, as in this case<sup>12</sup>. Although congenital malformations of the great toes are a constant feature of FOP, their presence is not pathognomonic<sup>1,2</sup>. In addition, it is possible to observe other alterations that this patient did not present, such as malformation of the thumbs, clinodactyly, tibial osteochondromas, and wide and short femoral necks<sup>1,5</sup>.

Affected patients develop episodic flare-ups of pain and soft tissue inflammation. Some episodes remit spontaneously, but in most of them, the soft connective tissues are transformed into bone tissue by endochondral ossification, leading progressively to permanent immobility. In addition, minor trauma, such as intramuscular immunizations, dental anesthesia, muscle fatigue, hematomas, falls, and infections, can trigger new flare-ups<sup>1,4</sup>.

As observed in this patient, heterotopic endochondral ossification progresses following anatomical and temporal patterns that mimic the patterns of bone formation in the normal human embryo. It initially occurs in the

dorsal, axial, cranial, and proximal regions of the body and is subsequently seen in the ventral, appendicular, caudal, and distal regions. Some skeletal muscles are unaffected, including the diaphragm, tongue, and extraocular muscles. Cardiac and smooth muscle tissues are also unaffected<sup>5,13</sup>.

Most patients require assistance with activities of daily living in the early stages. Mandibular involvement is usually followed by significant malnutrition. A frequent cause of death in affected patients is progressive cardiorespiratory failure due to thoracic insufficiency syndrome, which results in the inability of the thorax to achieve normal ventilation. The median age at death is 40 years<sup>13,14</sup>.

There is currently no definitive medical treatment for FOP. Therefore, management consists of supportive care. Since this is a chronic disease with a significant impact on quality of life, it is recommended that the care of patients with FOP be multidisciplinary<sup>1,15</sup>.

High doses of glucocorticoids have shown efficacy in the early treatment of flare-ups affecting the major joints, mandible, and submandibular region<sup>1,4</sup>. They also help prevent flare-ups after trauma and surgery, decreasing the probability of heterotopic ossification in the affected sites<sup>1,16</sup>. The administration is suggested in the first 24 hours of the outbreak, at a daily dose of 2 mg/kg/day, for no more than 4 days. This patient received corticosteroids and presented a good initial response.

Nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, mast cell stabilizers, and anti-leukotrienes are helpful in pain management<sup>17</sup>. Other drugs, such as bisphosphonates and imatinib, are not routinely used but may contribute to managing difficult-to-control flare-ups<sup>18</sup>.

New therapies are being investigated, including palovarotene derived from retinoic acid. This drug reduced the percentage of FOP patients who developed heterotopic ossification and is currently in a phase 3 study<sup>19</sup>.

Surgical interventions to remove heterotopic bone tissue result in reactive bone regrowth, as observed at the biopsy specimen extraction sites in this patient, and are therefore contraindicated<sup>1,10</sup>.

Preventive measures aimed at reducing flare-ups and subsequent ossification are essential. Patients with FOP should have prophylactic dental control, excluding mandibular anesthetic blocks. There is consensus on avoiding vaccination and intramuscular administration during flare-ups. Administration of vaccines with diphtheria, pertussis, and tetanus components, which are associated with a higher incidence of flare-ups, is not

routinely recommended<sup>20</sup>. For the same reason, muscle fatigue should be limited, and falls and respiratory infections should be prevented<sup>1,10</sup>.

In conclusion, FOP is a sporadic disease often underdiagnosed, especially in its early stages. If clinical suspicion exists, early molecular testing is suggested to detect the most frequent mutations of the *ACVR1* gene. Current management of FOP consists mainly of symptomatic treatment, maintenance of physical function, and family support.

## Ethical disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author has this document.

## Conflicts of interest

The authors declare no conflicts of interests.

## Funding

No funding.

## References

- Kaplan F, Al Mukkaddam M, Baujat G, Brown M, Cali A, Cho TJ, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. *Proc Intl Clin Council FOP*. 2019;1:1-111.
- Kaplan F, Le Merrer M, Glaser D, Pignolo R, Goldsby R, Kitterman J, et al. Fibrodysplasia ossificans progressiva. *Best Pract Res Clin Rheumatol*. 2008;22:191-205.
- Online Mendelian Inheritance in Man, OMIM®. Fibrodysplasia ossificans progressiva (FOP). Baltimore: Johns Hopkins University; 2017. Available from: <https://www.omim.org/entry/135100>
- Pignolo R, Bedford-Gay C, Liljeström M, Durbin-Johnson B, Shore E, Rocke D, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. *J Bone Miner Res*. 2016;31:650-6.
- Kaplan F, Xu M, Seemann P, Connor JM, Glaser D, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. *Hum Mutat*. 2009;30:379-90.
- Pérez C, Rodríguez M, Saráchaga ME. Fibrodysplasia ossificans progressiva: reporte de un caso. *Salud Militar*. 2015;34:60-4.
- Pignolo R, Shore E, Kaplan F. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. *Orphanet J Rare Dis*. 2011;6:80.
- Groppe JC, Shore EM, Kaplan FS. Functional modeling of the ACVR1 (R206H) mutation in FOP. *Clin Orthop Relat Res*. 2007;462:87-92.
- Ordóñez-Labastida V, Cárdenas-Conejo A, Huicochea-Montiel JC, Paredes-Rivera GE, Hidalgo-Bravo A, Monterde LMJ, et al. Clinical, radiological, and molecular diagnosis of progressive fibrodysplasia ossificans. *Bol Med Hosp Infant Mex*. 2021;78:234-8.
- Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. *Pediatrics*. 2005;116:e654-61.
- Bauer AH, Bonham J, Gutierrez L, Hsiao EC, Motamedi D. Fibrodysplasia ossificans progressiva: a current review of imaging findings. *Skeletal Radiol*. 2018;47:1043-50.
- Rampal V, Giuliano F. Forefoot malformations, deformities and other congenital defects in children. *Orthop Traumatol Surg Res*. 2020;106(1S):S115-S123.
- Pignolo RJ, Kaplan FS. Clinical staging of fibrodysplasia ossificans progressiva (FOP). *Bone*. 2017;109:111-4.
- Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. *J Bone Joint Surg Am*. 2010;92:686-91.
- de Ruiter RD, Smilde BJ, Pals G, Bravenboer N, Knaus P, Schoenmaker T, et al. Fibrodysplasia ossificans progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz Workshop. *Front Endocrinol (Lausanne)*. 2021;12:732728.
- Kaplan FS, Shore EM, Gupta R, Billings PC, Glaser DL, Pignolo RJ, et al. Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. *Clin Rev Bone Miner Metab*. 2005;3:189-93.
- Brunnekreef JJ, Hoogervorst P, Ploegmakers MJ, Rijnen WH, Schreurs BW. Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty? *Int Orthop*. 2013;37:583-7.
- Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, et al. Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases. *Bone*. 2018;109:276-80.
- Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. *Br J Clin Pharmacol*. 2019;85:1180-7.
- Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. *J Pediatr*. 1995;126:762-4.